Related Experiment Video
Updated: Feb 4, 2026

Surgical Models of Gastroesophageal Reflux with Mice
Published on: August 25, 2015
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
Maria Angeles Gil-Delgado1, Olivier Lucidarme2, Jean Baptiste Bachet3
1Medical Oncology Service, Groupe Hospitalier Pitié Salpêtrière, Paris, France.
Abstract:
We report a case of long-term survival with complete response of liver metastases within RAINBOW, a randomized, controlled trial of ramucirumab 8 mg/kg intravenously (days 1, 15) versus placebo, both plus paclitaxel 80 mg/m2 intravenously (days 1, 8, 15), every 4 weeks in patients with previously treated advanced gastroesophageal junction adenocarcinoma. A 64-year-old man with gastroesophageal junction adenocarcinoma and liver metastases received first-line folinic acid, 5-fluorouracil plus oxaliplatin (FOLFOX) following jejunostomy. On liver progression, he enrolled in RAINBOW (April 2012), receiving ramucirumab. In November 2013, positron emission tomography scan was consistent with complete metabolic response, confirmed by a follow-up scan in March 2016.
Related Concept Videos
Survival Curves
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
Survival Tree
Building a Survival Tree
Constructing a...
P-N junction
Long-term Depression
Gastroesophageal Reflux Disease I: Meaning and Pathophysiology
Introduction To Survival Analysis
The primary goal of survival analysis is to estimate survival time—the time...

